Sodium Chloride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sodium Chloride
- Sodium Chloride: From Intravenous Electrolyte Infusion Products to Breast Fibrocystic Disease
Sodium Chloride: From Intravenous Electrolyte Infusion Products to Breast Fibrocystic Disease
One-Sentence Summary
Sodium chloride is registered in South Africa as infusion and solution products, but the registration data do not state an approved indication. The TxGNN model predicts it may be effective for breast fibrocystic disease, with 1 clinical trial and 7 publications retrieved. None of this evidence tests sodium chloride as a treatment, so the prediction is model-only (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration data |
| Predicted New Indication | Breast fibrocystic disease |
| TxGNN Prediction Score | 96.79% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Sodium chloride is the main extracellular electrolyte in the body. No therapeutic mechanism links it to fibrocystic breast disease.
The retrieved literature mentions sodium chloride only as a measured component of breast cyst fluid. Cyst fluids are classified by their sodium/potassium ratio and chloride level, so sodium is a diagnostic biomarker, not a treatment effect.
The high score (0.968) most likely reflects how heavily sodium chloride is connected across the knowledge graph. It is unlikely to reflect a real therapeutic signal. Several other breast conditions in the prediction list (blunt duct adenosis, apocrine adenosis, benign mammary dysplasia) look like the same graph-neighbourhood effect.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02887937 | N/A | Completed | 135 | Contrast-enhanced ultrasound to assess indeterminate cystic breast masses and decide whether biopsy is needed. This is a diagnostic imaging study with no sodium chloride intervention. |
No SANCTR or PACTR registrations were retrieved.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2140797 | 1990 | Biochemical/cytological analysis | Eur J Surg Oncol | In 88 patients, cysts fell into three types by intracystic Na+/K+ ratio. Sodium is used to classify cysts, not to treat them. |
| 2015669 | 1991 | Biochemical analysis | Clin Chem | Cyst fluid protein GCDFP-70 was identified as albumin and used to classify cysts. |
| 9375824 | 1997 | Comparative fluid analysis | Nephron | Compared kidney (ADPKD) and breast cyst fluids, including sodium, chloride and amino acid content. |
| 10797312 | 2000 | In vitro | J Cell Physiol | Intracellular pH regulation in non-malignant and malignant breast cell lines. |
| 3369685 | 1988 | Laboratory study | Anal Biochem | Method for fractionating type V collagen from breast tissue using alkaline KCl. |
Two further retrieved papers were off-target and are not listed: a saline breast-implant reconstruction case series (PMID 3232934) and a lymphoma case report (PMID 23073330). No RCTs or systematic reviews were found.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. Z/24/107 | Neonatal maint solution spb0008 | Infusion |
| Reg. No. 85/23.4/3 | Sabax plasma vet 3000ml | Infusion |
| Reg. No. 36/34/0484 | Combibic Electrolyte Sol No/Potass 500 | Infusion |
| Reg. No. V/24/142 | Sustenance 1L fss001000ffx | Infusion |
| Reg. No. F/24/271 | Maintelyte 10% 1000m afb2774 | Infusion |
These are 5 of 20 registrations. The data do not include approved-indication text or Essential Medicines List (EML) status. Only injectable/infusion and solution forms are recorded, and no breast-directed or topical product is listed. “Sabax plasma vet” appears to be a veterinary product.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by model score. The single trial is a diagnostic imaging study, and the literature describes sodium as a cyst-fluid biomarker. There is no therapeutic mechanism, and none of the retrieved studies tests sodium chloride as a treatment for this condition.
To proceed, the following is needed:
- SAHPRA Professional Information (PI) for the registered products, to confirm approved indications, warnings and contraindications. Safety screening cannot start without it.
- Mechanism of action data (for example from DrugBank).
- Any clinical study that tests sodium chloride as the intervention in breast fibrocystic disease. Without one, this candidate should not advance.
Among the other nine predicted indications, only vulvovaginitis and vulvitis reached L4 (“Research Question”). That rating rests on one saline vaginal irrigation study (PMID 22301569) whose design and result could not be confirmed. The remaining seven are L5 with no supporting evidence.
This report is for research reference only and does not constitute medical advice. Any repurposing candidate requires clinical validation before use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.